Declaration of Voting Rights - Valneva SE, March 2024
VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue A
GlobeNewswireApr 4 12:00 ET
Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections
TipRanksMar 26 09:25 ET
Valneva Initiates Phase 1 Study Of Zika Virus Vaccine Candidate
RTTNewsMar 26 02:25 ET
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Saint-Herblain (France), March 25, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French
GlobeNewswireMar 25 02:00 ET
Valneva Is Maintained at Buy by Guggenheim
Valneva Is Maintained at Buy by Guggenheim
Dow JonesMar 22 14:09 ET
What Analysts Are Saying About Valneva Stock
Valneva (NASDAQ:VALN) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent ratings by
BenzingaMar 22 14:01 ET
Express News | Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17
Moomoo 24/7Mar 22 13:59 ET
Valneva Highlights Vaccine Advances at World Congress
TipRanksMar 22 07:00 ET
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 21 11:06 ET
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
BenzingaMar 21 06:42 ET
Valneva Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 248.06% HC Wainwright & Co. → $26 Reiterates Buy → Buy 02/29/2024 248.06% HC Wainwright & Co. →
BenzingaMar 21 06:40 ET
Buy Rating Affirmed for Valneva: Strong Core Growth and Strategic Financial Health
TipRanksMar 21 06:16 ET
Express News | Valneva To Present On Its Single-Shot Chikungunya Vaccine IXCHIQ, Participate In Multiple Events At The 24th World Vaccine Congress In Washington D.C
Moomoo 24/7Mar 21 02:10 ET
CuriosityStream Inc. Declares $0.025 Dividend
Seeking AlphaMar 20 16:38 ET
Earnings Call Summary | Valneva(VALN.US) Q4 2023 Earnings Conference
The following is a summary of the Valneva SE (VALN) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance data provided.Business Progress:No business progress updates provide
moomoo AIMar 20 16:33 ET · Conference Call
Valneva SE Announces Strong Financial Growth and R&D Progress
TipRanksMar 20 13:57 ET
Valneva GAAP EPS of -€0.73, Revenue of €153.71M; Updates FY24 Guidance
Seeking AlphaMar 20 04:13 ET
Valneva (VALN.US) Raises 2024 Product Sales Guidelines
The Zhitong Finance App learned that French biotech company Valneva (VALN.US) raised its product sales guidelines on Wednesday. Currently, product sales in 2024 are expected to be between 160 million euros and 180 million euros, higher than the previous forecast of 150 million euros to 180 million euros. Furthermore, the company estimates total revenue for 2024 to be between €170 million and €190 million. According to the data, Valneva's total revenue in 2023 was 153.7 million euros, lower than 2022's 361.3 million euros, which fell short of market expectations 1.
Zhitong FinanceMar 20 03:32 ET
Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M
Updated FY 2024 guidanceValneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an improved outlook regarding the IXIARO supply constraints that were anticipate
BenzingaMar 20 02:32 ET
Valneva FY Loss Narrows; Raises 2024 Product Sales Guidance
RTTNewsMar 20 02:29 ET
No Data
No Data